Why this call
Riding a Wave of Blockbuster Drugs
Exceptional revenue growth near 50%
Strong investor sentiment following positive drug data
Sustained price momentum over the past year
Weather forecast
Sunny
Buy
Score 70/100 · Confidence 78%
The outlook is bright — conditions favour stepping in.
Why this call
Exceptional revenue growth near 50%
Strong investor sentiment following positive drug data
Sustained price momentum over the past year
Under the hood
Six factors, scored 0–100 from live market and financial data — the same read Wall Street does, minus the jargon.
The stock's valuation is high, reflecting lofty market expectations.
Revenue growth is exceptional, among the best for a company of this size.
The company operates with excellent, best-in-class profit margins.
The stock is in a very strong and sustained uptrend at all timeframes.
The company's balance sheet carries a notable amount of debt.
Recent news flow has been constructive, focusing on positive clinical data.
The argument
Every call has a case against it. Here's the honest version of both.
The bull case
The bear case

Get the full picture
You just understood LLY without reading a single chart. The Tickerday app does this for your whole watchlist — the full thesis, price targets from next week to next year, bull and bear scenarios — and wakes you the moment the weather turns.
One plain answer for every stock — Buy, Hold, or Sell
The full picture in seconds — thesis, targets & scenarios
Sleep easy — we watch the market and wake you if it turns
Free to download the day it lands — the web desk is open now